The SARS-CoV-2 (COVID-19) pandemic has rapidly impacted cell therapy activities across the globe. Not only was this, unexpected event, a threat to patients who had previously received hematopoietic cell transplantation or other cell therapy such as CAR-T cells, but also, it was responsible for a disruption of cell therapy activities due to the danger of the virus and to the lack of solid scientific data on the management of patients and donors. The Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) devoted a workshop to issue useful recommendations in such an unexpected event in order to harmonize the actions of all the actors involved in cellular therapy programs so that we can collectively face, in the future, the challenges that could threaten our patients.
View Article and Find Full Text PDFSince 2010 there has been an exponential increase of the number of transplants performed from related donors. The development of haploidentical transplants increases the resort to related-donation, which presents two main advantages: a less important financial cost and a faster availability of the graft. Standards for mandatory accreditation exist, but the adherence to these recommendations is not optimal: currently, different practices regarding the organizational modalities of care, recruitment criteria, qualification and follow-up of related donors have been observed among French transplant centers.
View Article and Find Full Text PDFInternational literature endorses an organisation of care which links up the hospital and the usual living environment of the elderly person as well as interdisciplinarity in the pathway of these vulnerable patients. The internal medicine and vascular diseases department of Angers university hospital favours these two principles and wishes to strenghten this strategy thanks to the intervention of a dedicated nurse and an occupational therapist. The aim is to prevent the early rehospitalisation of elderly people.
View Article and Find Full Text PDF